Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03785743
Other study ID # TJDBPS07
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date May 1, 2027

Study information

Verified date February 2022
Source Tongji Hospital
Contact Renyi Qin
Phone +8602783665314
Email 172356995@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC. Minimally invasive surgery has been progressively developed, first with the advent of hybrid-laparoscopy and recently with the total laparoscopy surgeries, but a number of issues are currently being debated, including the superiority between total laparoscopic pancreaticoduodenectomy (TLPD)and the open pancreaticoduodenectomy (OPD). Studies comparing these two surgery techniques are merging and randomized controlled trials (RCT) are lacking but clearly required. Methods/design: TJDBPS07 is a multicenter prospective, randomized controlled, trial comparing TLPD and OPD in pancreatic cancers. A total of 200 patients with pancreatic cancer underwent PD will be randomly allocated to the TLPD group or OPD group with an enhanced recovery after surgery (ERAS) pattern. The trial's aim is to exploring the overall survival (OS), disease free survival (DFS) and quality of life. The duration of the entire trial is seven years including prearrangement, a presumably five-year follow-up and analyses. Discussion: Despite the fact there are several RCTs comparing minimally invasive pancreaticoduodenectomy (MIPD) and Open approach or LPD versus OPD. This trial will be the first comparing TLPD and OPD in a large multicenter setting. TJDBPS01 trial is hypothesized to assess whether TLPD has superiority over OPD in recovery and other aspects.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 1, 2027
Est. primary completion date March 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age between 18 years and 75 years. 2. Histologically confirmed PDAC or clinically diagnosed PDAC by an MDT without histopathologic evidence. 3. Patients feasible to undergo both LPD and OPD according to MDT evaluations. 4. Patients understanding and willing to comply with this trial. 5. Provision of written informed consent before patient registration. 6. Patients meeting the curative treatment intent in accordance with clinical guidelines. Exclusion Criteria: 1. Patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs. 2. Patients requiring left, central or total pancreatectomy or other palliative surgery. 3. Preoperative American Society of Anaesthesiologists (ASA) score = 4. 4. History of other malignant disease. 5. Pregnant or breast-feeding women. 6. Patients with serious mental disorders. 7. Patients treated with neoadjuvant therapy. 8. Patients with vascular invasion and requiring vascular resection as evaluated by the MDT team according to abdominal imaging data. 9. Body mass index > 35 kg/m2. 10. Patients participating in any other clinical trials within 3 months.

Study Design


Intervention

Procedure:
TLPD Surgery
TLPD
OPD Surgery
OPD

Locations

Country Name City State
China Department of Biliary and Pancreatic Surgery, Tongji Hospital, Affiliated Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (17)

Lead Sponsor Collaborator
Tongji Hospital Af?liated Hospital of North Sichuan Medical College, First Affiliated Hospital of Chongqing Medical University, Fudan University, Fujian Medical University Union Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Hunan Provincial People's Hospital, Peking Union Medical College Hospital, Shandong Provincial Hospital, Sir Run Run Shaw Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The Affiliated Hospital of Xuzhou Medical University, The First Hospital of Jilin University, The Second Hospital of Hebei Medical University, The Third Affiliated Hospital of Soochow University, Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5-year overall survival 5-year overall survival 5 year
Secondary overall survival the interval between the day of surgery and the day of death for various reasons 5 years
Secondary disease-free survival the interval between the day of surgery and the day of tumour recurrence 5 years
Secondary 90-day mortality the percentage of patients who died within 90 days postoperatively 90 days
Secondary complication rate complications related to PD 90 days
Secondary comprehensive complication index calculated as the sum of all complications that are weighted for their severity 90 days
Secondary length of stay the number of nights spent in the hospital from the end of the surgical procedure until discharge or death 90 days
Secondary intraoperative indicators description of the patients' intraoperative condition relating to the safety of patients 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT05613465 - Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo N/A
Completed NCT03645148 - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer Phase 1
Recruiting NCT02587689 - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor Phase 1/Phase 2
Active, not recruiting NCT02676349 - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) Phase 2
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Active, not recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Active, not recruiting NCT02009449 - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Phase 1
Terminated NCT03137706 - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Not yet recruiting NCT06080854 - AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer Phase 2
Completed NCT03962478 - Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction N/A
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Terminated NCT00907166 - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients Phase 1/Phase 2
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Completed NCT03949933 - Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer N/A
Recruiting NCT03711890 - Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer N/A